McCurdy, Arleigh http://orcid.org/0000-0002-8809-4368
Mian, Hira http://orcid.org/0000-0003-1584-1067
LeBlanc, Richard
Jimenez-Zepeda, Victor H.
Su, Jiandong
Masih-Khan, Esther
Visram, Alissa http://orcid.org/0000-0002-7201-4642
Louzada, Martha
Song, Kevin
White, Darrell
Sebag, Michael
Stakiw, Julie
Reiman, Anthony
Aslam, Muhammad
Bergstrom, Debra
Kotb, Rami
Kaedbey, Rayan
Gul, Engin
Reece, Donna
Venner, Christopher P.
Funding for this research was provided by:
This study was funded by CMRG through support from Janssen Canada Inc.
Article History
Received: 23 February 2023
Revised: 16 June 2023
Accepted: 11 July 2023
First Online: 20 July 2023
Change Date: 28 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-023-00888-6
Competing interests
: AM: Honoraria/Advisory fees: GSK, Janssen, BMS/Celgene, Forus therapeutics, Amgen, Takeda, Sanofi; research funding: BMS. HM: Honoraria/Advisory fees: GSK, Janssen, BMS/Celgene, Forus therapeutics, Amgen, Takeda, Sanofi; research funding: Janssen. RL: Honoraria/Advisory fees: Janssen, BMS, Amgen, Sanofi, Forus therapeutics. JS, EM-K, AR, MA, DB, and EG: None. AV: Honoraria/Advisory fees: Sanofi, Janssen, Apotex, Pfizer. ML: Honoraria: Janssen, BMS, Amgen and Pfizer. DW: Honoraria: Amgen, Antengene, BMS, Janssen, Karyopharm, Sanofi and Takeda. MS: Membership on an entity’s Board of Directors or advisory committees: Janssen Inc.; Amgen Canada; Takeda Canada; BMS Canada. RK: Research funding: Merck, Sanofi. Ownership/Share holder: Karyopharm. Honoraria: BMS, Janssen, Takeda, Amgen, Sanofi, Merck. DR: Honoraria/Advisory fees: BMS/Celgene, Janssen, Amgen, GSK, Sanofi, Forus Therapeutics, Takeda; research support: Jansen, BMS/Celgene, Takeda, Sanofi. CV: Honoraria: Janssen, Amgen, Takeda; research funding: BMS, Amgen. VJZ: Honoraria: Janssen, BMS/Celgene, Takeda, AMGEN, Forus therapeutics, Pfizer, Sanofi, GSK.